SEC EDGARSEP 161 min read$PHVS

Souverijns Wim sold $1.0M of PHVS

Souverijns Wim (Chief Commercial Officer) sold 26,090 shares of Pharvaris N.V. (PHVS) at an average of $39.23 ($38.99–$39.31, $1.02M total) across 2 trades over 2026-09-14 to 2026-09-15 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Souverijns Wim

Published Sep 16, 2026, 6:07 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 16, 2026, 6:56 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$PHVS

Bearish

medium confidence

Mentioned

$PHVS

Relevance

5/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$PHVSBearishLow

Why it matters

The sale reduces insider ownership and may be interpreted as a lack of confidence, potentially prompting short‑term selling pressure.

Market read

Insider sales are closely watched for signals; a $1M C‑level sale in a micro‑cap biotech is noteworthy for traders.

Timing

filed today

Relevance 5/10Novelty 6/10Timing: filed today

Background

SEC Form 4 filing discloses an insider sale by the company's Chief Commercial Officer.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$PHVSBearishMedium confidence

Context

Chief Commercial Officer sold 26,090 shares for $1.02M via a 10b5‑1 plan, reducing his stake to 39,021 shares.

Expected impact

Potential modest downside pressure over the next few days.

Evidence & confidence

C‑level insider selling $1M is material for a small‑cap biotech, but the amount is not large enough to trigger a sharp move.

Key entities

Company
Pharvaris N.V.
Biotech company listed on Nasdaq under ticker PHVS.
Insider
Souverijns Wim
Chief Commercial Officer of Pharvaris who executed the sale.

Read at source ← All news

OCT 26

$PHVSHighAI 9/10

Bank of America backs Pharvaris on breakthrough for rare swelling disease

Bank of America upgraded Pharvaris (PHVS) to Buy with a $44 price target, citing strong trial results for its HAE treatment drug, deucrictibant. The stock closed at $31.41 on Oct. 23. BofA sees substantial upside and notes positive feedback from doctors. The FDA decisions in 2027 could impact the stock.

finance.yahoo.com2 min

OCT 23

$PHVSMed

Pharvaris rises after BofA upgrades to Buy (PHVS:NASDAQ)

Pharvaris (PHVS) shares rose 3% premarket after BofA upgraded the stock to Buy from Neutral, citing its oral HAE potential. The brokerage kept its $44 price target. Pharvaris announced in September its.

seekingalpha.com1 min

OCT 23

$PHVSHigh

BofA upgrades Pharvaris stock rating on oral HAE treatment potential

BofA upgraded Pharvaris (PHVS) to Buy with a $44 price target, citing potential in its oral HAE treatment. The stock trades at $30.68, up 10.6% in a week. Positive phase 3 data and strong analyst ratings highlight its prospects, despite risks like market adoption and competition.

investing.com1 min

OCT 9

$PHVSHighAI 9/10

Pharvaris' Deucrictibant XR Cuts HAE Attack Rate By 83%; Plans NDA Filing In H1 2027

Pharvaris (PHVS) reported that its Phase 3 study of deucrictibant XR for hereditary angioedema (HAE) met all endpoints, reducing attack rates by 83%. The company plans to file for FDA approval in H1 2027. PHVS stock closed at $31.12, up 0.58% in after-hours trading.

rttnews.com3 min

OCT 8

$PHVSMedAI 8/10

Pharvaris HAE drug shows faster symptom relief in Lancet study

Pharvaris' phase 3 study of deucrictibant IR for HAE attacks, published in The Lancet, met all endpoints, showing faster symptom relief and resolution than placebo. The drug was well-tolerated. FDA and EMA reviews are ongoing with decisions expected in 2027. According to the company, the study results support the drug's efficacy and safety.

investing.com5 min